Track Intensity Therapeutics Inc. Common stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Intensity Therapeutics Inc. Common stock INTS · Stock Open Intensity Therapeutics Inc. Common stock in new tab

3.08 USD
EPS
-3.48
P/B
0.66
ROE
-195.88
Beta
3.04
Target Price
18.67 USD
Loading chart...
Key Metrics
Earnings dateMarch 18, 2027
EPS-3.48
Book Value4.70
Price to Book0.66
Debt/Equity1.03
% Insiders3.917%
Estimates
Forward P/E-1.40
Forward EPS-2.21
Target Mean Price18.67

DCF valuation

Model fair value for Intensity Therapeutics Inc. Common stock (INTS)
Result
Sign in to run the valuation for INTS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus Strong buy · mean target 18.67 USD (low 7.00, high 32.00) · as of 11 Nov 2026
Low 7.00
Mean 18.67
High 32.00
Price 3.08
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Intensity Therapeutics Inc. Common stock Logo Intensity Therapeutics Inc. Common stock Analysis (INTS)

United States Health Care Official Website Stock

Is Intensity Therapeutics Inc. Common stock a good investment? Intensity Therapeutics Inc. Common stock (INTS) is currently trading at 3.08 USD. Market analysts have a consensus price target of 18.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Intensity Therapeutics Inc. Common stock is expected to release its next earnings report on March 18, 2027. The market consensus estimate for Forward EPS is -2.21.

Investor FAQ

Does Intensity Therapeutics Inc. Common stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Intensity Therapeutics Inc. Common stock?

Intensity Therapeutics Inc. Common stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 18, 2027. The company currently has a trailing EPS of -3.48.

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Exchange Ticker
NMS (United States) INTS
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Feb. 19, 2026 1:25
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion